Kallidinogenase (Tissue Kallikrien) in Complex Therapy in Patients with Isolated Closed Traumatic Brain Injury

Аvakov V. E., Ibragimov N. K., Murotov TM. N.

dc.contributor.author	Аvakov V. E., Ibragimov N. K., Murotov TM. N.
dc.date.accessioned	2023-01-30T06:25:02Z
dc.date.available	2023-01-30T06:25:02Z
dc.date.issued	2022-12-04
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/6201
dc.description.abstract	Closed isolated traumatic brain injury (ТBI) is a major medical and social problem due to its high prevalence, high rates of mortality and disability, as well as the economic costs of treatment, rehabilitation and social assistance to victims [1]. Considering the severity of this disease and the insufficient effectiveness of conventional methods of treatment, we studied the effectiveness of the drug Kallidinogenase (tissue kallikrein) in complex therapy in patients with closed isolated traumatic brain injury.	en_US
dc.language.iso	en_US	en_US
dc.publisher	American Journal of Medicine and Medical Sciences	en_US
dc.subject	CTBI, Tissue kallikrein (kallidinogenase), ICP, CPP, GLASGOW scale, SAPS II, APACHE II	en_US
dc.title	Kallidinogenase (Tissue Kallikrien) in Complex Therapy in Patients with Isolated Closed Traumatic Brain Injury	en_US
dc.type	Article	en_US